中文
| Catalogue |
|
|
| Recommend Products |
CEVEC Pharmaceuticals GmbH
Germany, Manufacturer, Hits: 1083, Updated:4/16/2020
Germany |
Company Profile
-
CEVEC has developed the first stable AAV Producer Cell Line Technology which stably incorporates the sequences of the serotype-specific capsid and the gene of interest into the genome of the cell. The helper virus-free platform based on suspension cells delivers a consistent quality of AAV vectors over time due to the elimination of any transfection step.
CEVEC’s?CAP? Technology?based on human suspension cells is the ideal production platform for RCA-free adeno viral vectors, oncolytic viruses, viral vaccines and exosomes.
With?CAP? Go?CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors, and plasma proteins.
Company News
- CEVEC and UCB Sign Agreement for the Use of CEVEC’s ELEVECTA® AAV Manufacturing Technology in... 9/15/2021
- CEVEC Announces the Launch of the ELEVECTA® Platform – the Stable Producer Cell Line Technolo... 4/28/2020
- CEVEC Signs License Agreement for the Development and Commercialization of Exosomes for Therapeuti... 4/16/2020